The mood was pretty somber going into Heartware’s (Framingham, Mass.) breakout session during the 34th annual J.P.Morgan Healthcare conference. But why wouldn’t it be? It’s not everyday that a med-tech CEO has to discuss halting a European trial on one of its most promising technologies. But that’s exactly what Doug Godshall, Heartware president/CEO did. Godshall, who took the leadership position of Heartware in 2006, delivered the bad news across a sea of somewhat disenchanted faces during the conference. He did a great job, but honestly, is there ever a “good way” to deliver bad news? You see, Godshall revealed...

Jan Medical (Mountain View, Calif.), a private company, has scored $7.5 million in series C funding, to help navigate its Brainpulse technology through the regulatory path.

Staff Writer Biotheranostics (San Diego), a specialist in the molecular diagnostics for cancer market, said it raised $32 million and will be spun out from Biomérieux SA (Marcy-l'Étoile, France). The financing was led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and Healthquest Capital.